<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604890</url>
  </required_header>
  <id_info>
    <org_study_id>CTL0108</org_study_id>
    <nct_id>NCT00604890</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma</brief_title>
  <official_title>Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berg, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Berg, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of pharmaceutical
      compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to
      obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by
      API 31510 topical cream. The study population will include one hundred and sixty (160)
      otherwise healthy male or female adults with one or more histologically confirmed superficial
      basal cell carcinoma lesions. One target lesion with an area of less than one inch will be
      designated for study treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Response</measure>
    <time_frame>10 weeks</time_frame>
    <description>To determine the number of participants with a complete response, defined as a negative histological examination of the sBCC lesion at Week 10 (4 weeks post-treatment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Partial Response</measure>
    <time_frame>10 weeks</time_frame>
    <description>To determine the number of participants with a partial response, defined as a clinically significant decrease (ie, at least 50%) in the area of the sBCC lesion, computed as the product of the two principal diameters at Week 10 (4 weeks post-treatment)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Superficial Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active cream, 3% AM &amp; PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream AM ; 3% active cream PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream AM; 1.5% active cream PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo AM and PM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>API 31510 3% Topical Cream</intervention_name>
    <description>Topical treatment 3% active cream applied to the lesion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>API 31510 1.5% Topical Cream</intervention_name>
    <description>Topical treatment 1.5% active cream applied to the lesion</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical treatment placebo applied to the lesion</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults â‰¥ 18 years of age

          -  Primary, histologically confirmed sBCC with a minimum area of 0.5 cm2 and with a
             maximum diameter of 2.0 cm target sBCC lesion suitable for excision

          -  Histological diagnosis made no more than 4 weeks prior to the screening visit

          -  Histological biopsy removed 25% or less of the target lesion

          -  No other dermatological disease in the sBCC target site or surrounding area

          -  Willing to refrain from using non-approved lotions or creams on the target site and
             surrounding area during the treatment period. Willing to refrain from washing the
             treated area for at least 8 hours following the application of study medication

          -  Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid
             the use of tanning parlors for the duration of the study

          -  Laboratory values for the tests listed in the Study Schedule on page 2 within the
             reference ranges as defined by the central laboratory, or &quot;out of range&quot; test results
             that are clinically acceptable to the investigator.

          -  Ability to follow study instructions and likely to complete all study requirements

          -  Written informed consent obtained, including consent for tissue to be examined and
             stored by the central dermatopathologist

          -  Written consent to allow photographs of the target sBCC lesion to be used as part of
             the study data

          -  For females of childbearing potential, a negative pregnancy test at screening and
             using an acceptable form of birth control (oral/implant/injectable/transdermal
             contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous
             relationship with a partner who has had a vasectomy)

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Presence of known or suspected systemic cancer

          -  Histological evidence of nBCC, SCC, or any other tumor in the biopsy specimen

          -  Histological evidence of severe squamous metaplasia, infiltrative, desomoplastic or
             micronodular growth patterns in the biopsy specimen

          -  History of recurrence of the target sBCC lesion

          -  Evidence of dermatological disease or confounding skin condition in the treatment
             area, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema,
             xeroderma pigmentosa

          -  Concurrent disease or treatment that suppresses the immune system

          -  Chronic medical condition that in the judgment of the investigator(s) would interfere
             with the performance of the study or would place the patient at undue risk

          -  Known sensitivity to any of the ingredients in the study medication

          -  Use of a tanning parlor or other excessive or prolonged exposure to ultraviolet light
             or direct sunlight during the course of the study

          -  Treatment with systemic chemotherapeutic agents within the 6 months prior to the
             screening visit

          -  Use of systemic retinoids within the 6 months prior to the screening period

          -  Treatment with systemic immunomodulators or immunosuppressants within the 6 months
             prior to the screening period

          -  Use of topical immunomodulators within 2 cm of the target BCC lesion within the 4
             weeks prior to the screening period

          -  Treatment with the following topical agents within the 4 weeks prior to the screening
             visit: levulanic acid, 5-fluorouracil, coricosteroids, retinoids, diclofenac,
             hyaluronic acid, imiquimod

          -  Undergone a facial resurfacing procedure, i.e., chemical peel, laser resurfacing,
             dermabrasion, within the 6 months prior to the screening visit, if the target sBCC
             lesion is on the face

          -  Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the
             target sBCC lesion during the 4 weeks prior to the screening visit

          -  Elective surgery within 4 weeks prior to the screening visit, during the study, or 4
             weeks after the treatment period

          -  Evidence of current chronic alcohol or drug abuse

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within 4 weeks of the screening visit

          -  In the investigator's opinion, evidence of unwillingness, or inability to follow the
             restrictions of the protocol and complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Education and Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burke Pharmaceuticals</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Surgery Medical Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates and Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Clinical Research</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott D. Glazer, M.D., S.C.</name>
      <address>
        <city>Buffalo Grove</city>
        <state>Illinois</state>
        <zip>60089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Clinic</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Skin Cancer and Dermatologic Surgery, PC</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Education &amp; Research Foundation</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <results_first_submitted>January 22, 2019</results_first_submitted>
  <results_first_submitted_qc>February 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double-Blind</keyword>
  <keyword>Placebo</keyword>
  <keyword>Topical</keyword>
  <keyword>Treatment</keyword>
  <keyword>Dose-Ranging</keyword>
  <keyword>sBCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3% Active Cream BID(Twice Daily)</title>
          <description>Topical Treatment 3.0% active cream applied to the lesion twice daily (BID)</description>
        </group>
        <group group_id="P2">
          <title>3% Active Cream QD(Once Daily)</title>
          <description>Topical treatment 3.0% active cream applied to the lesion once daily (PM) plus placebo cream applied to the lesion once daily (AM)</description>
        </group>
        <group group_id="P3">
          <title>1.5% Active Cream QD(Once Daily)</title>
          <description>Topical treatment 1.5% active cream applied to the lesion once daily (PM) plus placebo cream applied to the lesion once daily (AM)</description>
        </group>
        <group group_id="P4">
          <title>Placebo BID(Twice Daily)</title>
          <description>Placebo cream applied to the lesion twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3% BID</title>
          <description>3.0% active twice daily (BID)</description>
        </group>
        <group group_id="B2">
          <title>3% QD</title>
          <description>3.0% active cream once daily (QD) plus placebo cream QD</description>
        </group>
        <group group_id="B3">
          <title>1.5% QD</title>
          <description>1.5% active cream once daily (QD) plus placebo cream QD</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo cream twice daily (BID)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="46"/>
            <count group_id="B5" value="186"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" lower_limit="36" upper_limit="83"/>
                    <measurement group_id="B2" value="61.2" lower_limit="34" upper_limit="84"/>
                    <measurement group_id="B3" value="60.4" lower_limit="34" upper_limit="81"/>
                    <measurement group_id="B4" value="62.8" lower_limit="37" upper_limit="90"/>
                    <measurement group_id="B5" value="61.7" lower_limit="34" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Response</title>
        <description>To determine the number of participants with a complete response, defined as a negative histological examination of the sBCC lesion at Week 10 (4 weeks post-treatment).</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3% Active Cream BID</title>
            <description>3.0% active cream twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>3% Active Cream QD</title>
            <description>3.0% active cream once daily (QD) plus placebo cream QD</description>
          </group>
          <group group_id="O3">
            <title>1.5% QD</title>
            <description>1.5% active cream once daily (QD) plus placebo cream QD</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo cream twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response</title>
          <description>To determine the number of participants with a complete response, defined as a negative histological examination of the sBCC lesion at Week 10 (4 weeks post-treatment).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Partial Response</title>
        <description>To determine the number of participants with a partial response, defined as a clinically significant decrease (ie, at least 50%) in the area of the sBCC lesion, computed as the product of the two principal diameters at Week 10 (4 weeks post-treatment)</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3% Active Cream BID</title>
            <description>3.0% active cream twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>3% QD</title>
            <description>3.0% active cream once daily (QD) plus placebo cream QD</description>
          </group>
          <group group_id="O3">
            <title>1.5% QD</title>
            <description>1.5% active cream once daily (QD) plus placebo cream QD</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo cream twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Partial Response</title>
          <description>To determine the number of participants with a partial response, defined as a clinically significant decrease (ie, at least 50%) in the area of the sBCC lesion, computed as the product of the two principal diameters at Week 10 (4 weeks post-treatment)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>3% Active Cream BID</title>
          <description>3.0% active cream twice daily (BID)</description>
        </group>
        <group group_id="E2">
          <title>3% QD</title>
          <description>3.0% active cream once daily QD plus placebo cream QD</description>
        </group>
        <group group_id="E3">
          <title>1.5% QD</title>
          <description>1.5% active cream once daily (QD) plus placebo cream QD</description>
        </group>
        <group group_id="E4">
          <title>Placebo BID</title>
          <description>Placebo cream twice daily (BID)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Blockage ( L ) Anterior Artery/Percutaneous Coronary Intervention (Stent) # 6 = Primary Care</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Etythema</sub_title>
                <description>The most frequently reported treatment-emergent AE was application site erythema, which was reported in 33 of 186 subjects (17.7 %) in the overall safety population</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Application Site Dryness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Application Site Exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nathaniel DiTommaso</name_or_title>
      <organization>Berg LLC</organization>
      <phone>617-588-1002</phone>
      <email>nate.ditommaso@berghealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

